Literature DB >> 26966009

L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.

Oscar Solís1,2, Patricia García-Sanz1,2, Antonio S Herranz3, María-José Asensio3, Rosario Moratalla4,5.   

Abstract

Perturbations in the cerebral levels of various amino acids are associated with neurological disorders, and previous studies have suggested that such alterations have a role in the motor and non-motor symptoms of Parkinson's disease. However, the direct effects of chronic L-DOPA treatment, that produces dyskinesia, on neural tissue amino acid concentrations have not been explored in detail. To evaluate whether striatal amino acid concentrations are altered in peak dose dyskinesia, 6-hydroxydopamine (6-OHDA)-lesioned hemiparkinsonian mice were treated chronically with L-DOPA and tissue amino acid concentrations were assessed by HPLC analysis. These experiments revealed that neither 6-OHDA nor L-DOPA treatment are able to alter glutamate in the striatum. However, glutamine increases after 6-OHDA and returns back to normal levels with L-DOPA treatment, suggesting increased striatal glutamatergic transmission with lack of dopamine. In addition, glycine and taurine levels are increased following dopamine denervation and restored to normal levels by L-DOPA. Interestingly, dyskinetic animals showed increased levels of GABA and tyrosine, while aspartate striatal tissue levels are not altered. Overall, our results indicate that chronic L-DOPA treatment, besides normalizing the altered levels of some amino acids after 6-OHDA, robustly increases striatal GABA and tyrosine levels which may in turn contribute to the development of L-DOPA-induced dyskinesia.

Entities:  

Keywords:  Abnormal involuntary movements; GABA; Glutamate; Glutamine; Glycine; Parkinson’s disease; Taurine; Tyrosine

Mesh:

Substances:

Year:  2016        PMID: 26966009     DOI: 10.1007/s12640-016-9612-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  52 in total

1.  Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites.

Authors:  Andreas Heuer; Gaynor A Smith; Mariah J Lelos; Emma L Lane; Stephen B Dunnett
Journal:  Behav Brain Res       Date:  2011-11-28       Impact factor: 3.332

2.  Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.

Authors:  Irene Ruiz-DeDiego; Britt Mellstrom; Mario Vallejo; Jose R Naranjo; Rosario Moratalla
Journal:  Biol Psychiatry       Date:  2014-03-27       Impact factor: 13.382

3.  Free amino acids in the brain of patients with Parkinson's disease.

Authors:  J O Rinne; T Halonen; P J Riekkinen; U K Rinne
Journal:  Neurosci Lett       Date:  1988-11-22       Impact factor: 3.046

4.  ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.

Authors:  Nancy Pavón; Ana B Martín; Ainhoa Mendialdua; Rosario Moratalla
Journal:  Biol Psychiatry       Date:  2005-09-01       Impact factor: 13.382

5.  Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.

Authors:  Simone Bido; Matteo Marti; Michele Morari
Journal:  J Neurochem       Date:  2011-08-05       Impact factor: 5.372

6.  Dopaminergic regulation of olfactory type G-protein α subunit expression in the striatum.

Authors:  I Ruiz-DeDiego; J R Naranjo; D Hervé; R Moratalla
Journal:  Mov Disord       Date:  2015-03-15       Impact factor: 10.338

7.  Parkinson disease: from pathology to molecular disease mechanisms.

Authors:  David T Dexter; Peter Jenner
Journal:  Free Radic Biol Med       Date:  2013-02-04       Impact factor: 7.376

8.  Tyrosine-free amino acid mixtures reduce physiologically-evoked release of dopamine in a selective and activity-dependent manner.

Authors:  Marisa Le Masurier; Tyra Zetterström; Philip Cowen; Trevor Sharp
Journal:  J Psychopharmacol       Date:  2013-10-09       Impact factor: 4.153

9.  Optimal excitation and emission wavelengths to analyze amino acids and optimize neurotransmitters quantification using precolumn OPA-derivatization by HPLC.

Authors:  J Perucho; R Gonzalo-Gobernado; E Bazan; M J Casarejos; A Jiménez-Escrig; M J Asensio; A S Herranz
Journal:  Amino Acids       Date:  2015-02-18       Impact factor: 3.520

10.  Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.

Authors:  Tim Fieblinger; Steven M Graves; Luke E Sebel; Cristina Alcacer; Joshua L Plotkin; Tracy S Gertler; C Savio Chan; Myriam Heiman; Paul Greengard; M Angela Cenci; D James Surmeier
Journal:  Nat Commun       Date:  2014-10-31       Impact factor: 14.919

View more
  11 in total

1.  Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.

Authors:  Oscar Solís; Jose-Rubén García-Montes; Patricia Garcia-Sanz; Antonio S Herranz; Maria-José Asensio; Gina Kang; Noboru Hiroi; Rosario Moratalla
Journal:  Neurobiol Dis       Date:  2017-03-16       Impact factor: 5.996

2.  Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.

Authors:  M Feher; B Gaszner; A Tamas; A L Gil-Martinez; E Fernandez-Villalba; M T Herrero; D Reglodi
Journal:  Neurotox Res       Date:  2017-12-11       Impact factor: 3.911

3.  Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP+ Toxicity In Vivo.

Authors:  Natalia Moreno-Galarza; Liliana Mendieta; Victoria Palafox-Sánchez; Mireia Herrando-Grabulosa; Carles Gil; Daniel I Limón; José Aguilera
Journal:  Neurotox Res       Date:  2018-02-19       Impact factor: 3.911

Review 4.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

Review 5.  Loss and remodeling of striatal dendritic spines in Parkinson's disease: from homeostasis to maladaptive plasticity?

Authors:  Rosa M Villalba; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-05-24       Impact factor: 3.575

6.  Astrocytes modulate extracellular neurotransmitter levels and excitatory neurotransmission in dorsolateral striatum via dopamine D2 receptor signaling.

Authors:  Louise Adermark; Oona Lagström; Anna Loftén; Valentina Licheri; Amy Havenäng; Eleonora Anna Loi; Rosita Stomberg; Bo Söderpalm; Ana Domi; Mia Ericson
Journal:  Neuropsychopharmacology       Date:  2021-11-22       Impact factor: 8.294

7.  Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.

Authors:  José-Rubén García-Montes; Oscar Solís; Juan Enríquez-Traba; Irene Ruiz-DeDiego; René Drucker-Colín; Rosario Moratalla
Journal:  Mol Neurobiol       Date:  2018-09-27       Impact factor: 5.590

Review 8.  Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia.

Authors:  Oscar Solís; Rosario Moratalla
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

9.  The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients.

Authors:  Tommaso Nuzzo; Daniela Punzo; Paola Devoto; Elena Rosini; Silvia Paciotti; Silvia Sacchi; Qin Li; Marie-Laure Thiolat; Celine Véga; Massimo Carella; Manolo Carta; Fabrizio Gardoni; Paolo Calabresi; Loredano Pollegioni; Erwan Bezard; Lucilla Parnetti; Francesco Errico; Alessandro Usiello
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

10.  Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease.

Authors:  Daniel Stoessel; Claudia Schulte; Marcia C Teixeira Dos Santos; Dieter Scheller; Irene Rebollo-Mesa; Christian Deuschle; Dirk Walther; Nicolas Schauer; Daniela Berg; Andre Nogueira da Costa; Walter Maetzler
Journal:  Front Aging Neurosci       Date:  2018-03-05       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.